Laboratory Corporation of America: Plasma Phosphorylated-Tau 217

Laboratory Corporation of America this week introduced its plasma phosphorylated-tau 217 (p-tau 217) test to aid in the diagnosis of Alzheimer's and the monitoring of patients being treated with Alzheimer's therapies. The test is meant for use by physicians and in clinical trials and research by global biopharmaceutical partners. The test is performed using a Fujirebio Lumipulse chemiluminescent enzyme immunoassay.